The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 30, 2005
Filed:
Jul. 12, 2002
Alan Hutchison, Madison, CT (US);
George Maynard, Clinton, CT (US);
Pamela Albaugh, Carmel, IN (US);
Linghong Xie, Guilford, CT (US);
Jun Yuan, Guilford, CT (US);
Scott Mitchell, East Haven, CT (US);
Vinod Singh, Kanpur, IN;
Manuka Ghosh, Madison, CT (US);
Guiying LI, Branford, CT (US);
Nian Liu, North Branford, CT (US);
Alan Hutchison, Madison, CT (US);
George Maynard, Clinton, CT (US);
Pamela Albaugh, Carmel, IN (US);
Linghong Xie, Guilford, CT (US);
Jun Yuan, Guilford, CT (US);
Scott Mitchell, East Haven, CT (US);
Vinod Singh, Kanpur, IN;
Manuka Ghosh, Madison, CT (US);
Guiying Li, Branford, CT (US);
Nian Liu, North Branford, CT (US);
Neurogen Corporation, Branford, CT (US);
Abstract
This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds, such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines, imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or Formula II: The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Processes for preparing compounds of Formula I and Formula II are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I or Formula II in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAreceptors in tissue sections.